You will feel like crap using letro, especially off cycle. I would try Raloxifene 1st. 60mgs ed for 2 months, it's a SERM, so it won't crush your estrogen like letro will. Crushed estrogen is not fun.I am running the letro mainly because i have had a mild case of gyno since puberty. I dont know if will be as effective as i hope but i figure now would be the best time to try it out since im coming off an aas. Ill admit, im guilty of not fully researching the proper use of the letro. I should have used it while on the Mdrol. From what ive researched, i think i am going to start the clomid. What doses of the letro and clomid would suit my situation best? And is it ok to run them together? I took 0.5mg letro today. Ive read so many different opinions on this... But
This is the plan for the letro. So give me your thoughts...
Day 1: .50mg
Day 2: 1.0mg
Day 3: 1.5mg
Day 4: 2.0mg
Day 5: 2.5mg
Remaining at 2.5mg up to 5 days after gyno is gone and then begin a 5 day taper down with the same dosages as the build up.
Thanks for the help
i just told you, letro shuts you down..... post cycle therapy (pct) is useless if ur doing letro... thats like doing post cycle therapy (pct) while on a test cycle....
What exactly does letro shut down?
Effects of aromatase inhibition on luteinizing hormone release and testosterone production
It is well known from experimental evidence and from clinical observations that estradiol has powerful effects on gonadotropin release in men. Modulation of plasma estradiol levels within the male physiological range is associated with strong effects on plasma levels of LH through an effect at the level of the pituitary gland [32]. Lowering estradiol levels, by administering an aromatase inhibitor, is associated with an increase in levels of LH, follicle-stimulating hormone (FSH) and testosterone [28,29]. Aromatase inhibitors, therefore, have been sug- gested as a tool to increase testosterone levels in men with low testosterone levels. Due to their mode of action the use of aromatase inhibitors is limited to men with at least some residual function of the hypothalamo-pitui- tary-gonadal axis. Therefore aromatase inhibitors have been tested in older men suffering from so-called late- onset hypogonadism or partial androgen deficiency. Aging in men is associated with a gradual decline of total and free testosterone levels [33] as a result of com- bined testicular and hypothalamic dysfunction. The decline of testosterone levels has been implicated in the pathogenesis of physical frailty in older men. Androgen treatment, therefore, has been advocated for older men with signs and symptoms of androgen deficiency and unequivocally low plasma testosterone levels [34,35].
Aromatase inhibitors may be an attractive alternative for traditional testosterone substitution in elderly men because these compounds can be administered orally once daily and may result in physiological 24 h testoster- one profiles.
Diabetes Obes Metab. 2005 May;7(3):211-5.
Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism.
de Boer H, Verschoor L, Ruinemans-Koerts J, Jansen M.
Source
Department of Internal Medicine, Ziekenhuis Rijnstate, Wagnerlaan 55, 6800 TA Arnhem, The Netherlands. hdeboer@alysis.nl
Abstract
BACKGROUND:
Morbid obesity is associated with increased estradiol production as a result of aromatase-dependent conversion of testosterone to estradiol. The elevated serum estradiol levels may inhibit pituitary LH secretion to such extent that hypogonadotropic hypogonadism can result. Normalization of the disturbed estradiol-testosterone balance may be beneficial to reverse the adverse effects of hypogonadism.
AIM:
To examine whether aromatase inhibition with Letrozole can normalize serum testosterone levels in severely obese men with hypogonadotropic hypogonadism.
PATIENTS AND METHODS:
Ten severely obese men, mean age 48.2 +/- 2.3 (s.e.) years and body mass index 42.1 +/- 2.6 kg/m(2), were treated with Letrozole for 6 weeks in doses ranging from 7.5 to 17.5 mg per week.
RESULTS:
Six weeks of treatment decreased serum estradiol from 120 +/- 20 to 70 +/- 9 pmol/l (p = 0.006). None of the subjects developed an estradiol level of less than 40 pmol/l. LH increased from 4.5 +/- 0.8 to 14.8 +/- 2.3 U/l (p < 0.001). Total testosterone rose from 7.5 +/- 1.0 to 23.8 +/- 3.0 nmol/l (p < 0.001) without a concomitant change in sex hormone-binding globulin level. Those treated with Letrozole 17.5 mg per week had an excessive LH response.
CONCLUSION:
Short-term Letrozole treatment normalized serum testosterone levels in all obese men. The clinical significance of this intervention remains to be established in controlled, long-term studies.
PMID: 15811136 [PubMed - indexed for MEDLINE]